Isolate Data
| Patient | Isolate | Region | Year | Species | Subtype | Source | Clone Method |
| AS-34 | AS-34 | U.S. | 1998 | HIV1 | B | Plasma | None |
Treatment History
| Order | Regimen | Weeks |
| 1 | AZT | 21 |
| 2 | DDC+AZT | 30 |
| 3 | 3TC+AZT | 56 |
| 4 | 3TC+D4T+NFV | 58 |
Protease Sequence
| PIMajorDRMs | PIMinorDRMs | Polys | UnusualMuts |
| I13V, K20T, E35D, M36I, L63P, A71V, I93L |
| >AS-34| codons 1-99 PQITLWQRPLVTVKIGGQLTEALLDTGADDTVLEDINLPGRWKPKMIGGIGGFIKVRQYD QIPIEICGHKVIGTVLVGPTPVNIIGRNLLTQLGCTLNF >AS-34| C1 | codons 1-99 | clone C1 PQITLWQRPLVTVKIGGQLTEALLDTGADDTVLEDINLPGRWKPKMIGGIGGFIKVRQYD QIPIEICGHKVISTVLVGPTPVNIIGRNLLTQLGCTLNF >AS-34| C2 | codons 1-99 | clone C2 PQITLWQRPLVTVKIGGQLTEALLDTGADDTVLEDINLPGGWKPKMIGGIGGFIKVRQCD QVPIEICGHKAIGTVLVGPTPVNIIGRNLMTQLGCTLNF >AS-34| C3 | codons 1-99 | clone C3 PQITLWQRPLVTVKIGGQLTEALLDTGADDTVLEDINLPGRWKPKMIGGIGGFIKVRQYD QIPIEICGHKVIGTVLVGPTPVNIIGRNLMTQIGCTLNF >AS-34| C4 | codons 1-99 | clone C4 PQITLWQRPLVTVKIGGQLTEALLDTGADDTVLEDINLPRRWKPKTIGGIGGFIKVRQYD QVPIEICGHKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF >AS-34| C5 | codons 1-99 | clone C5 PQITLWQRPLVTVKIGGQLTEALLDTGADDTVLEDINLPGRWKPKMIGGIGGFIKVRQYD QIPIEICGHKTIGTVLVGPTPVDIIGRNLLTQLGCTLNF >AS-34| C6 | codons 1-99 | clone C6 PQITLWQRPLVTVKIGGQLTEALLDTGADDTVLEDINLPGRWKPKMIGGIGGFIKVRQYD QMPIEICGHKVISTVLVGPTPVNIIGRNLLTQLGCTLNF >AS-34| C7 | codons 1-99 | clone C7 PQITLWQRPLVTVKIGGQLTEALLDTGADDTVLEDINLPGRWKPKMIGGIGGFIKVRQYD QIPIEICGHKVISTVLVGPTPVNIIGRNLLTQLGCTLNF |
RT Sequence
| NRTIMajorDRMs | NRTIMinorDRMs | NNRTIMajorDRMs | NNRTIMinorDRMs | Polys | UnusualMuts |
| M41L, K70R, M184V | T69N, R83K, K122E, T200A, R211K |
| >AS-34| codons 1-229 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTELEKEGKISKIGPENPYNTPV FAIKKKDSNRWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPL DEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVI YQYVDDLYVGSDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLW >AS-34| C1 | codons 1-229 | clone C1 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTELEKEGKISKIGPENPYNTPV FAIKKKDSNRWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPL DEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVI YQYVDDLYVGSDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLW >AS-34| C2 | codons 1-229 | clone C2 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTELEKEGKISKIGPENPYNTPV FAIKKKDSNRWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPL DEDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIII YQYVDDLYVGSDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLW >AS-34| C3 | codons 1-229 | clone C3 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTELEKEGKISKIGPENPYNTPV FAIKKKDSNRWRELVDFRGLNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYLSVPL DKDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIII YQYVDDLYVGSDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLW >AS-34| C4 | codons 1-229 | clone C4 PISPIETVPVKLRPGMDGPKVKQWPLTEEKIKALVEICTELEKEGKISKIGPENPYNTPV FAIKKKDSNRWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPL DEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVI YQYVDDLYVGSDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLW >AS-34| C5 | codons 1-229 | clone C5 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTELEKEGKISKIGPENPYNTPV FAIKKKDSNRWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPL DEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVI YQYVDDLYVGSDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLW >AS-34| C6 | codons 1-229 | clone C6 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTELEKEGKISKIGPENPYNTPV FAIKKKDSNRWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPL DEDFRKYTAFTIPSINNEAPGIRYQYNVLPQGWKGSPAIFRSSMTKILEPFRKQNPDIVI YQYVDDLYVGSDLEIGQHRTKIEELGQHLLKWGFTTPDKKHQKEPPFLW >AS-34| C7 | codons 1-229 | clone C7 PISPIETVPVKLKPGMDGPKVKQRPLTEEKIKALVEICTELEKEGKISKIGPENPYNTPV FAIKKKDSNRWRKLVDFRELNKKTQDFWEVPLGIPHPAGLKKKKSVTVLDVGDAYFSVPL DEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVI YQYVDDLYVGSDLEIGQHRAKIEELRQHLLKWGFTTPDKEHQKEPPFLW |
References
| Author | Title | Citation |
| Saah, AJ | Treatment with indinavir, efavirenz, and adefovir after failure of nelfinavir therapy. | J Infect Dis, 2003 |
| Rhee, SY | HIV-1 Protease and Reverse Transcriptase Mutations: Correlations with Antiretroviral Therapy in Subtype B Isolates and Implications for Drug-Resistance Surveillance. | J Infect Dis, 2005 |